|
業務類別
|
Biotechnology |
|
業務概覽
|
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies. |
| 公司地址
| 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850 |
| 電話號碼
| +1 240 745-6330 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.novabridge.com |
| 員工數量
| 30 |
| Mr. Ming Kyler Lei |
Chief Financial Officer |
-- |
07/04/2026 |
| Ms. Liwei Lorraine Lin |
General Counsel and Board Secretary |
-- |
07/04/2026 |
| Dr. Phillip Dennis, M.D.,PhD |
Chief Medical Officer |
-- |
07/04/2026 |
| Dr. Xi-Yong Sean Fu |
Chief Executive Officer and Director |
-- |
07/04/2026 |
| Dr. Wuxiong Sean Cao, PhD |
Chief Business Development Officer and Director |
-- |
07/04/2026 |
| Dr. Cong Claire Xu |
Senior Vice President and Head, R&D Center of Excellence |
-- |
07/04/2026 |
|
|
| Dr. Emmett Cunningham, M.D.,M.P.H.,PhD |
Vice Chairman of the Board |
07/04/2026 |
| Mr. Wei Fu |
Executive Chairman of the Board |
07/04/2026 |
| Dr. Xi-Yong Sean Fu |
Chief Executive Officer and Director |
07/04/2026 |
| Dr. Wuxiong Sean Cao, PhD |
Chief Business Development Officer and Director |
07/04/2026 |
| Dr. Robert Lenz, M.D. |
Independent Director |
07/04/2026 |
| Mr. Chia-Hung Conor Yang |
Independent Director |
07/04/2026 |
| Ms. Xin Liu |
Independent Director |
07/04/2026 |
| Mr. Ian Ying Woo |
Director |
07/04/2026 |
| Mr. Chun Kwok Alan Au |
Independent Director |
07/04/2026 |
|
|
|
|
